Psoralidin

立即咨询

Psoralidin

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

18642-23-4

包装与价格：

包装	价格(元)
10 mM * 1 mL in DMSO	电议
5mg	电议
10mg	电议
50mg	电议
100mg	电议

产品名称

补骨脂定

产品介绍

Psoralidin 是COX-2和5-LOX的双重抑制剂。具有抗癌，抗菌和抗炎作用。Psoralidin 显著下调NOTCH1信号传导。Psoralidin 还极大地诱导ROS产生。

生物活性

Psoralidin is a dual inhibitor ofCOX-2and5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties^[1]. Psoralidin significantly downregulatesNOTCH1signaling. Psoralidin also greatly inducesROSgeneration^[2].

IC₅₀& Target^[1]

COX-2

5-LOX

体外研究
(In Vitro)

Three breast cancer cell (BCC)populations (ALDH^-cells, ALDH⁺cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25 μM; 24 hours) with IC₅₀s ranging from 18 to 21 μM; however, the MCF-12A cells were resistant to Psoralidin^[2].
Psoralidin (30 μM; 24 hours) results in a significant induction of apoptosis for ALDH^-cells, ALDH⁺cells, and commercial BCSCs^[2].
Psoralidin treatment also downregulates NOTCH1 expression in both ALDH^-and ALDH⁺cells^[2].

Cell Viability Assay^[2]

Cell Line:	ALDH^-cells, ALDH⁺cells, commercial breast cancer stem cells (BSCSs), and normal breast epithelial cells (MCF-12A)
Concentration:	10, 15, 50, and 25 μM
Incubation Time:	24 hours
Result:	IC₅₀s of 18 to 21 μM for ALDH^-cells, ALDH⁺cells, commercial BCSCs.

Apoptosis Analysis^[2]

Cell Line:	ALDH^-cells, ALDH⁺cells, and commercial BCSCs
Concentration:	20 and 30 μM
Incubation Time:	24 hours
Result:	No significant induction of apoptosis was observed for any of the three cell types following treatment at 20 μM. However, 53.60%, 44.1%, and 45.9% of cells were apoptotic at 30 μMin ALDH^-cells, ALDH⁺cells, and commercial BCSCs, respectively.

体内研究
(In Vivo)

Psoralidin (5 mg/kg) regulates expression of pro-inflammatory cytokines that play an important role in inflammatory diseasesin IR-irradiated lung of BALB/c mouse^[1].

Animal Model:	BALB/c mice^[1]
Dosage:	5 mg/kg
Administration:	Intraperitoneal application; 30 min before and 1 h after IR irradiation (20 Gy).
Result:	Anti-inflammatory effect in IR-irradiated mice.

分子量

336.34

性状

Solid

Formula

C₂₀H₁₆O₅

CAS 号

18642-23-4

中文名称

补骨脂定；补骨脂次素

结构分类

Phenols
Polyphenols

来源

Plants
Leguminosae
Psoralea corylifoliaL.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 50 mg/mL(148.66 mM;ultrasonic and warming and heat to 60℃)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	2.9732 mL	14.8659 mL	29.7318 mL
5 mM	0.5946 mL	2.9732 mL	5.9464 mL
10 mM	0.2973 mL	1.4866 mL	2.9732 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline
Solubility: 2.08 mg/mL (6.18 mM); Suspended solution; Need ultrasonic
此方案可获得 2.08 mg/mL (6.18 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
2.
请依序添加每种溶剂： 10% DMSO 90%corn oil
Solubility: ≥ 2.08 mg/mL (6.18 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.18 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在本网站选购。